POS0831 MALIGNANCIES RISK IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB OR TNF INHIBITORS, A NATIONAL STUDY: RELATION STUDY
Authors: J. E. Gottenberg, M. Kessouri, J. Rudant, N. Assi, F. Raguideau, J. Kirchgesner
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Patients with IMID, and notably patients with rheumatoid arthritis RA, are at increased risk of cancer compared with the general population [1,2]. It is hence paramount to assess the impact of biological or targeted DMARD (e.g.., tofacitinib and TNFi) on the risk of cancer outcome in patients already at-risk, particularly in the context of ORAL Surveillance which showed a higher risk for malignancies (excluding nonmelanoma skin cancer, NMSC) with tofacitinib, in comparison with TNFI, in RA patients [3]. <h3>Objectives</h3> To assess the impact of tofacitinib and TNFi on the risk of malignancies in patients with RA treated in real-world clinical practice. <h3>Methods</h3> The RELATION study is a retrospective observational cohort study using the French nationwide healthcare database (SNDS). Patients aged 18 years or older, affiliated to the national health insurance with a diagnosis of RA and initiating tofacitinib after November 1, 2017 or TNFi after January 1, 2010 (including adalimumab, etanercept, or other TNFi, without previous exposure to tofacitinib) were followed from treatment initiation to December 31, 2020. Patients with a previous history of a malignancy (excluding NMSC) in the 4 years preceding cohort entry were excluded. All malignancies events were defined by the first hospitalization for malignancy during follow-up. Comorbidities and traditional cardiovascular (CV) risk factors were identified using hospitalizations, procedures, or medication dispensing in the 4 years prior cohort entry. The unadjusted incidence rate (IR) of malignancies (excluding NMSC) was assessed in patients initiating either tofacitinib or a TNFi (with associated 95% confidence intervals (95% CI)). A 1:3 PS matching was conducted to balance the baseline characteristics of patients initiating tofacitinib and TNFi. Cox proportional hazards regression models were used to compare the risk of malignancy with tofacitinib vs TNFi during the follow-up period. <h3>Results</h3> Between 2010 and 2020, a total of 39,578 patients with RA were included in the study. Among these, 2,811 initiated tofacitinib and 36,767 initiated a TNFi (adalimumab: 10,621, etanercept: 16,512, other TNFi: 9,634). Patients had a mean age of 53 years at cohort entry, and 72% to 81% were women. Around 61% of the cohort had at least one CV risk factor (66.3%for tofacitinib compared to 60.9% for TNFi). The two major co-medications at treatment initiation in the two groups were methotrexate (60.9%) and corticosteroids (50.8%). After PS matching, the tofacitinib cohort included 2,628 patients, and the TNFi cohort included 7,884 patients. Over a median follow-up period of 11.31 months (tofacitinib: 8.56 months, TNFi: 12.52 months), 15 incident malignancy events occurred in the tofacitinib group (IR: 5.89 (3.55–9.77) per 1,000 patient-year (PY)) and 135 occurred in the TNFi group (8.03 (6.78–9.50)). The risk of malignancies was similar with tofacitinib vs TNFi (adjusted HR 0.76 [95%CI 0.44, 1.32]; p=0.3347). Similar results were found for other (other than breast, melanoma, colorectal, lung cancer or lymphoma) active cancers (HR 0.97 [95% CI 0.50, 1.89]; p=0.9382). For other specific cancer types (cited above), the number of events was too low to perform these analyses. <h3>Conclusion</h3> In this large population-based study, tofacitinib was not associated with an increased risk of malignancies (excluding NMSC) in comparison with TNFI in patients with RA treated in real-world settings. Studies with longer follow-up durations may be necessary to understand the long-term implications of tofacitinib vs TNFi on the risk of malignancies. <h3>References</h3> [1]Smitten AL et al. Arthritis Res Ther 2008; 10: 1-8. [2]Simon TA et al. Arthritis Res Ther 2015; 17: 1-0. [3]Ytterberg SR et al. N Engl J Med 2022; 386: 316-26. <h3>Acknowledgements</h3> This study was sponsored by Pfize.r. <h3>Disclosure of Interests</h3> Jacques-Eric Gottenberg Consultant of: AbbVie, Bristol Myers Squibb, Galapagos, Gilead, Lilly, MSD, Novartis, Pfizer , Grant/research support from: Pfizer, Bristol Myers Squibb, Meriem Kessouri Shareholder of: Pfizer, Employee of: Pfizer, Jeremie Rudant Shareholder of: Pfizer, Employee of: Pfizer, Nada Assi Employee of: Heva, Fanny Raguideau Employee of: Heva, Julien Kirchgesner Speakers bureau: Pfizer, Consultant of: Gilead, Pfizer, Roche.